Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Sage Therapeutics and Biogen formally pursue FDA approval for zuranolone for depression

By Brian Buntz | May 3, 2022

Sage and BiogenSage Therapeutics (Nasdaq:SAGE) and Biogen (Nasdaq: BIIB) have begun a rolling submission of a New Drug Application (NDA) to FDA for zuranolone to treat major depressive disorder (MDD).

The two companies plan on submitting additional clinical data for the NDA in the second half of the year.

Biogen entered into a $1.5 billion licensing agreement with Sage Therapeutics to commercialize zuranolone (SAGE-217) and SAGE-324 in late 2020.

Zuranolone is an oral neuroactive steroid GABA-A receptor positive allosteric modulator (PAM).

In Phase 3 clinical trials, zuranolone 50 mg is administered daily for 14 days.

In addition to MDD, Sage and Biogen plan on pursuing approval for zuranolone in PPD starting next year.

The drug candidate won Fast Track Designation from the FDA in 2017 in MDD and Breakthrough Therapy Designation a year later.

Data were positive from the LANDSCAPE and NEST clinical trial programs.

“Zuranolone has the potential to help address a significant unmet medical need in depression as an innovative option in a therapeutic area where little has changed in the past 30 years,” said Dr. Priya Singhal, head of global safety and regulatory sciences and interim head of R&D at Biogen, in a statement.

While the drug candidate appears to have a rapid therapeutic effect, questions remain about the durability of the drug’s antidepressant effect, as a February Reuters article observed.

The SHORELINE trial, which is part of the LANDSCAPE clinical program, is assessing the need for repeat dosing for up to 12 months.


Filed Under: clinical trials, Psychiatric/psychotropic drugs
Tagged With: Biogen, Sage Therapeutics, zuranolone
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

psilocybin
Psilocybin holds therapeutic promise — but tapping its potential could be a challenge
Compass Pathways
Psilocybin therapy shows promise for treating anorexia and depression in small studies
Psilocybin
Psilocybin lit up the brains of people with severe depression in small study
Clearmind
Clearmind aims to use a psychedelic to treat alcoholism

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50